Trial Profile

A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel with or without RAD001 in Patients with Triple-negative Locally Advanced Breast Cancer (SPORE)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Cisplatin; Paclitaxel
Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms SPORE

Most Recent Events

07 Mar 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
06 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
14 Dec 2013 Primary analysis presented at the 36th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com